Eikon Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EIKN | AVBP | OLMA | CCCC | ORIC | 2410.HK | |
|---|---|---|---|---|---|---|
| Market cap | 346.11M | 665.16M | 659.73M | 383.84M | 968.12M | 1.21B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.0 | -3.6 | -2.9 | -3.4 | -5.5 | -6.1 |
| Price/book | 0.7 | 1.8 | 1.5 | 1.6 | 2.5 | 4.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −57.40% | −26.64% | −7.94% | +31.09% | −25.58% | −80.24% |
| Today | +15.14% | +3.61% | +2.59% | −2.80% | −2.61% | +9.61% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EIKN news ›Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
BOULDER, Colo., Oct. 8, 2026 – Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 –…
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Cohort 1A: Updated EIK1003 monotherapy data Cohort 1B: Initial data on EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Cohort 1C: Updated data on EIK1003 in combination with weekly paclitaxel…
Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to…
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical c... Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate…
Eikon Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Eikon Therapeutics (EIKN) with a Buy rating and $23 price target Eikon is a clinical-stage biopharmaceuti... Eikon Therapeutics initiated with a Buy at H.C. Wainwright H.C. Wainwright initiated…
Eikon Therapeutics submits EIK1006 IND application to FDA
Eikon Therapeutics (EIKN) announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the tr... Eikon Therapeutics submits EIK1006 IND application to FDA Eikon Therapeutics (EIKN)…
Computer-designed acridine compounds show predicted binding to breast cancer estrogen receptor
An entirely computational study reports that three designed 9-anilinoacridine derivatives show favourable predicted binding to estrogen receptor-alpha, with compound II(f) prioritized on the basis of MM-GBSA energetics and molecular…
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Selected 0.60 mg/m 2 as the single dose for the ...
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs,…
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline
HAYWARD, Calif. – Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired exclusive rights to multiple…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- investors.eikontx.com2
- markets.financialcontent.com2
- marketbeat.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.